Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 16/20 | 1.00 |
| ▸ | MMP13 | P45452 | 4/20 | 0.75 |
| ▸ | MMP2 | P08253 | 4/20 | 0.75 |
| ▸ | MMP9 | P14780 | 3/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6322594 | 0.92 | ADAM17 (1.00) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL6319361 | 0.91 | ADAM17 (1.00) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL6318995 | 0.90 | ADAM17 (1.00) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL6325055 | 0.88 | ADAM17 (1.00) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL6319318 | 0.88 | ADAM17 (0.83) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL6318592 | 0.88 | ADAM17 (1.00) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL6322233 | 0.88 | ADAM17 (1.00) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL6325076 | 0.87 | ADAM17 (1.00) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL6318449 | 0.87 | ADAM17 (0.83) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL6319255 | 0.86 | ADAM17 (1.00) | ADAM17MMP13MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936620-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-30 | — | — | US | claimed |
| US-20050171185-A1 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION | 2005-08-04 | — | — | US | claimed |
| US-20050171185-A1 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION | 2005-08-04 | — | — | US | disclosed |
| EP-1070705-A1 | INDOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171185-A1 | Indole derivatives | PDE5A, IGFBP5, HTR5A | ADAM17 2599/4885MMP13 1416/4885MMP2 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.